My Pharma Reviews

Elon Musk, the man scaling AI to outperform PhDs on GPQA Diamond (94% vs humans’ 69%) via Colossus and Terafab, says his biggest hiring mistake was overweighting IQ. Now? He hires for “goodness of heart” which is the untrainable drive to do right when no one’s watching. Intelligence is commoditizing as cheap AI bots beat experts on the toughest science benchmarks.

What’s scarce? Character.

In India’s $30B domestic pharma boom (12% CAGR, facing 28% US tariffs), this flips things. PE allocators today vet founders for ethical moats. Leaders don’t yet filter teams Musk-style - no resumes, just integrity stress-tests. Students must prioritise building character over rote-learning now.

AI replicates brains not souls. Your last edge? Character.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

The global pharmaceutical industry is no longer a linear value chain. It is rapidly becoming a bipolar ecosystem anchored by the United States and China. The US continues to dominate breakthrough innovation and capital formation, while China is integrating R&D, manufacturing, and market scale into a powerful, state-backed engine. In this emerging order, the “middle layer” is thinning out. Companies and countries reliant on cost arbitrage or incremental generics are increasingly exposed.

For Indian pharma, this is a moment of strategic clarity. The question is no longer about incremental upgrades to the generics model, but about repositioning in a polarized world moving into biologics, building integrated capabilities, and leveraging regulatory trust as a global differentiator. For investors and CXOs alike, the next decade will reward those who shift from volume-driven growth to capability-led value creation.

Listen and share.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

A LinkedIn post said that AZ head honcho, Pascal Soriot warned that Europe risks becoming a “mere sales office” for pharmaceuticals. It sounds so familiar to us in India, that it is tempting to dismiss it as predictable industry pushback.

It would be a mistake.

Beneath the rhetoric lies discomfort. Europe is not being outcompeted. It is systematically opting out of the innovation economy that it claims to lead. And Germany (the continent’s economic anchor) is about to accelerate that shift.

Listen in for details.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

There’s a familiar lament inside Indian pharma boardrooms and brand team reviews - “Our hands are tied. We can’t say what we want. We can’t do what we want.” Regulation is framed as friction, an external constraint imposed by cautious bureaucracies on otherwise agile, market-driven organizations.

That thinking is not just incomplete, it is strategically erroneous. Because in every mature, high-trust industry from financial services to aviation to medtech, regulation is not the enemy of growth. It is the architecture of advantage. Successful companies have not worked around regulation, they built capabilities through it.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

India's pharma journey began not with market serendipity, but with deliberate statecraft post-independence. In the 1950s, amid dire poverty, the Second Five Year Plan commissioned the Ayyangar Committee to blueprint an indigenous drug industry. This was sophisticated strategy, not naive idealism. The committee recommended process patents over product patents, freeing Indian firms to reverse-engineer foreign drugs without infringing intellectual property - a move echoing South Korea's playbook of nurturing infant industries through temporary protections.

The real radicalism hit in the late 1960s and 1970s, under Indira Gandhi's left-leaning regime. India repealed product patents entirely via the 1970 Patents Act, unleashing a 30-year window of regulatory arbitrage. Small, nimble companies like Ranbaxy and Cipla exploded, fueled by directed credit from public banks and a talent pool from an improbably vast expansion of IITs, IISc, and medical colleges. These institutions churned out inexpensive PhDs and engineers far beyond immediate domestic needs, creating a "bench" of scientific firepower.

Aggressive entrepreneurs pounced. Ranbaxy, for instance, poached talent from decaying public-sector units like Hindustan Antibiotics. By the 1990s, as global pressure mounted (think WTO TRIPS negotiations), India signaled patent reinstatement by 2005. This carrot-and-stick dynamic forced firms outward: from domestic generics to US-FDA approvals and complex molecules. Exports surged, peaking at sophisticated injectables and biotech. By 2020, Indian pharma commanded 40% of US generics, a triumph of policy-fueled aggression.

India's pharma proves manufacturing revival is feasible without waiting for perfect markets. But glory fades without reinvention.

Echoing pharma's Ayyangar origins, India needs a "Tech Ayyangar Committee" for deep integration. Triple R&D tax credits for AI spends; create $5B sovereign fund for quantum/AI scale-ups. Prioritize talent: 10x bioinformatics programs at IISERs, targeting 1M skilled workers by 2030. Public-private hubs like "Pharma 4.0 Valleys" in Hyderabad/Bengaluru could mirror Shenzhen's tech clusters.

India's pharmaceutical sector stands at a pivotal juncture, where deep tech integration can propel it from generics powerhouse to innovation leader. By embedding AI, IoT, and advanced analytics into core processes, pharma can slash R&D timelines by 30-50%, boost manufacturing efficiency, and unlock personalized medicine at scale. This isn't incremental digitization, it's a full re-orchestration, intertwining tech so profoundly that processes become autonomous, predictive, and patient-centric. The payoff: a "different orbit" by 2030, with India capturing high-margin novel drugs and biosimilars amid global demand.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

There is a shift underway in how we understand power, risk, and execution in the modern world. It sits at the intersection of three ideas that, at first glance, seem unrelated - (i) Nassim Nicholas Taleb’s concept of fat tails, (ii) the increasing replacement of human judgment with systems, and (iii) Ukraine’s evolving doctrine of fighting a war with fewer boots on the ground.

But together, they describe the same underlying truth that we are moving from a world that rewards scale and predictability to one that punishes fragility and rewards asymmetry. The world is moving that way - wonder when we will catch up. Listen in for more fun.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

Over the past decade, China has reduced its exposure to US government debt from ~$1.3 trillion to under $700 billion while steadily accumulating gold. Not as a trade. Not as a hedge. But as a statement on geopolitics. When war broke out in Ukraine, the West froze a large portion of Russia’s reserves and fundamentally changed how sovereign nations think about risk. Suddenly, “safe assets” carried political conditions. And diversification became less about yield and more about control.

Gold, in that context, is not just a commodity. It is neutral. It cannot be sanctioned, frozen, or weaponized. But let’s not overstate the shift. The US dollar, backed by the scale and depth of United States markets, still anchors the global financial system. There is no real substitute yet. This is de-risking, not de-dollarization.

The dollar is not likely to collapse, but a parallel system will rise. One where countries hedge their dependence, build alternative rails, and prepare for a world where finance and geopolitics are no longer separable. There it is not about what is the safest asset? It is about what is beyond control?

Why not cryptocurrency? That’s for another episode.

Further reading is encouraged.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

Anthropic appointed Vas Narasimhan to its board on April 14, 2026, making him the first pharmaceutical industry executive to join the AI startup’s governing body. Critically, he was appointed by the Anthropic Long-Term Benefit Trust an independent body whose members have no financial stake in Anthropic, and with his addition, Trust-appointed directors now make up a majority of the board. This is a clear and strong governance signal.

A signal for what? Listen to this podcast for more on the topic.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

Healthcare isn’t fintech or e-commerce. You can’t disrupt trust overnight. And that’s where the Bajaj name changes the equation.

Trust, built over decades in financial services and insurance, is now being extended into healthcare. That’s a powerful advantage in a sector where credibility is everything.

As patients begin to trust new orchestrators of care, will pharma evolve into a patient partner or remain a product company watching the front-end slip away? I know that answer, I suspect you do too!

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

Careers - pharma and elsewhere - followed the logic of the 10,000-hour rule popularized by Malcolm Gladwell in his book “Outliers”. Learn the science, build relationships, accumulate experience, and over time, expertise will emerge. But that model was always built on an assumption that repetition leads to mastery.

In reality, pharma was never a repetition-driven industry, it was a cycle-driven one. You don’t become an expert by doing the same thing better. You become one by navigating launches, failures, regulatory shocks, and market shifts. Hours were never the real currency, exposure to meaningful decisions was.

AI is now dismantling the “10,000-hour layer” within pharma roles. Listen.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com